What we offer
A New First Step in
the Lung Cancer Pathway
Inflammacheck® brings fast, accessible screening into primary care, enabling earlier referral and intervention when outcomes are most favourable.
Detecting cancer early, without harm
Inflammacheck® offers patients a gentle, non-invasive breath test that can indicate early signs of lung cancer without radiation or discomfort. For healthcare providers, the device requires no specialist training and produces results instantly, fitting seamlessly into routine consultations. This means earlier detection, faster decision-making, and fewer missed opportunities for timely treatment. By replacing invasive or resource-heavy first-line tests, Inflammacheck makes the process safer and easier for both patients and professionals.
Screening where it’s needed most
Lung cancer prevalence is highest in populations that often face barriers to care. Inflammacheck® overcomes these barriers by being portable, affordable, and simple to use in community settings.
Patients can be screened in GP surgeries, pharmacies, or outreach clinics without travelling to specialist centres. This widens access to those in deprived areas and underserved groups, helping reduce health inequalities. For society, it means more people can benefit from early detection, levelling up access to life-saving screening.
Smarter screening, better value
Inflammacheck® provides a cost-effective way to identify individuals at risk of lung cancer before committing to expensive imaging. By reducing unnecessary CT scans, it saves healthcare systems both time and resources while lowering patient exposure to radiation. The device’s low operating cost and ease of use make it suitable for widespread deployment, even in resource-limited settings. For healthcare providers and payers, this means screening becomes financially sustainable at scale. For society, it means healthier outcomes at lower cost.